at an average burn rate of between $600k to $700k per mo., the remaining amount of COH last time I checked would get them into Jan., 2015, on a float of 768-Mil. - now fast approaching 800-Mil. Thats one thing I've got to say about Gerald & Faerber - they have no problem going to 'equity distribution' for their continued funding.

Contrarily, per Dave's astute post, I suspect this maybe the last ticket we have to start our trek to GC's promised land:

Quote:

---

"Professor: If LymPro does what we all think it will do in 2015, AMBS won't run out of money. That's why everyone is on pins and needles about all of Lympro's delays. If management can deliver LymPro and successfully launch it in December with strong data, a marketing blitz, and several clinical trial work orders....we'll all be fine."

---